Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ARQT

ARQT - Arcutis Biotherapeutics Inc Stock Price, Fair Value and News

9.68USD+0.06 (+0.62%)Market Closed
Watchlist

Market Summary

USD9.68+0.06
Market Closed
0.62%

ARQT Alerts

  • Point72 Asset Management, L.P. reported owning 5.1% of ARQT [2024-01-31]

ARQT Stock Price

View Fullscreen

ARQT RSI Chart

ARQT Valuation

Market Cap

908.0M

Price/Earnings (Trailing)

-3.39

Price/Sales (Trailing)

242.74

Price/Free Cashflow

-3.46

ARQT Price/Sales (Trailing)

ARQT Profitability

Operating Margin

12.48%

Return on Equity

-573.4%

Return on Assets

-91.44%

Free Cashflow Yield

-28.9%

ARQT Fundamentals

ARQT Revenue

Revenue (TTM)

3.7M

Rev. Growth (Qtr)

634.28%

ARQT Earnings

Earnings (TTM)

-267.9M

Earnings Growth (Yr)

58.44%

Earnings Growth (Qtr)

36.94%

Breaking Down ARQT Revenue

Last 7 days

41.6%

Last 30 days

155.5%

Last 90 days

355.9%

Trailing 12 Months

-44.2%

How does ARQT drawdown profile look like?

ARQT Financial Health

Current Ratio

6.72

Debt/Equity

4.3

Debt/Cashflow

-1.3

ARQT Investor Care

Shares Dilution (1Y)

54.91%

Diluted EPS (TTM)

-4.37

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20230000
20220003.7M

Tracking the Latest Insider Buys and Sells of Arcutis Biotherapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 13, 2024
matsuda masaru
acquired
-
-
119,550
see remark
Feb 13, 2024
watanabe todd franklin
acquired
-
-
264,882
see remarks
Feb 13, 2024
burnett patrick
acquired
-
-
189,050
see remarks
Feb 13, 2024
smither john w
acquired
-
-
11,365
chief financial officer
Feb 13, 2024
moore matthew richard
acquired
-
-
94,898
svp and chief business officer
Jan 12, 2024
matsuda masaru
acquired
-
-
28,000
see remark
Jan 12, 2024
watanabe todd franklin
acquired
-
-
125,000
see remarks
Jan 12, 2024
edwards larry todd
acquired
-
-
28,000
chief commercial officer
Jan 12, 2024
burnett patrick
acquired
-
-
28,000
see remarks
Jan 12, 2024
moore matthew richard
acquired
-
-
28,000
svp and chief business officer

1–10 of 50

Which funds bought or sold ARQT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 20, 2024
Quarry LP
unchanged
-
-6,240
9,690
-%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
new
-
242,000
242,000
0.02%
Feb 16, 2024
HARBOUR INVESTMENTS, INC.
unchanged
-
-62.00
97.00
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
100
27,000
149,000
-%
Feb 16, 2024
VIMA LLC
new
-
17,610
17,610
0.04%
Feb 15, 2024
BARCLAYS PLC
reduced
-47.53
-748,000
351,000
-%
Feb 15, 2024
Farther Finance Advisors, LLC
new
-
32.00
32.00
-%
Feb 15, 2024
Virtus ETF Advisers LLC
sold off
-100
-49,107
-
-%
Feb 15, 2024
Legal & General Group Plc
reduced
-80.48
-204,793
27,590
-%
Feb 15, 2024
JANE STREET GROUP, LLC
added
30.54
-134,522
518,741
-%

1–10 of 45

Are Funds Buying or Selling ARQT?

Are funds buying ARQT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ARQT
No. of Funds

Unveiling Arcutis Biotherapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
prudential financial inc
10.47%
0
SC 13G/A
Feb 13, 2024
polar capital holdings plc
6.67%
6,297,688
SC 13G/A
Feb 13, 2024
suvretta capital management, llc
9.99%
9,534,837
SC 13G/A
Feb 13, 2024
vanguard group inc
5.19%
4,896,513
SC 13G
Feb 12, 2024
morgan stanley
6.5%
6,093,497
SC 13G
Feb 12, 2024
rubric capital management lp
7.04%
6,644,530
SC 13G
Feb 08, 2024
jennison associates llc
9.6%
9,066,082
SC 13G
Jan 31, 2024
point72 asset management, l.p.
5.1%
4,836,116
SC 13G
Jan 29, 2024
blackrock inc.
6.3%
5,916,546
SC 13G
Jan 23, 2024
state street corp
1.62%
1,525,045
SC 13G/A

Recent SEC filings of Arcutis Biotherapeutics Inc

View All Filings
Date Filed Form Type Document
Feb 15, 2024
4
Insider Trading
Feb 15, 2024
4
Insider Trading
Feb 15, 2024
4
Insider Trading
Feb 15, 2024
4
Insider Trading
Feb 15, 2024
4
Insider Trading
Feb 15, 2024
8-K
Current Report
Feb 15, 2024
SC TO-I/A
SC TO-I/A
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
SC 13G/A
Major Ownership Report

Peers (Alternatives to Arcutis Biotherapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
37.9B
9.1B
-16.59% -47.80%
-10.94
4.16
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
20.5B
1.8B
-23.99% -31.71%
-46.58
11.22
76.23% 61.08%
16.9B
2.3B
-4.89% -18.90%
115.27
7.33
15.05% 75.21%
13.7B
3.7B
-7.62% -26.87%
22.88
3.7
8.87% 75.42%
MID-CAP
8.0B
272.9M
-2.06% 34.31%
-13.22
29.35
141.38% 4.43%
6.5B
-
-3.85% 226.12%
-10.45
60.35
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.42
6.46
23.54% 31.53%
3.8B
223.4M
8.92% 47.81%
-18.87
17.04
-35.86% -26.24%
3.7B
240.7M
-19.08% -10.99%
-12.61
15.54
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.89
4.25
81.69% -7.29%
579.7M
1.0B
-9.17% -57.89%
-1.06
0.55
-43.15% 58.48%
174.3M
4.9M
-14.18% -58.18%
-1.06
35.65
-57.57% 50.48%
112.6M
881.7K
289.54% 381.25%
-2.37
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Arcutis Biotherapeutics Inc News

Latest updates
InvestorsObserver29 hours ago
InvestorsObserver14 Feb 202408:00 am

Arcutis Biotherapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q3
Revenue634.3%38,1095,1902,7811,753725
Cost Of Revenue52.3%1,182776783485269
Operating Expenses4.3%75,01371,95379,04671,385105,473
  S&GA Expenses3.6%47,59545,95842,91837,02335,473
  R&D Expenses4.0%26,23625,21935,34533,87769,731
Interest Expenses2.9%7,5597,3497,0426,9154,899
Income Taxes-3,023----
Net Income36.9%-44,765-70,991-80,100-72,019-107,709
Net Income Margin19.0%-72.67*-89.75*-88.78*-84.50*-
Free Cashflow34.0%-44,048-66,761-80,426-71,188-67,701
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q4
Assets-8.6%293321379449509300364408387433471298198232254107
  Current Assets-8.8%282309368437497295359403382428466293194228254106
    Cash Equivalents2.2%10710581.0054.0083.0063.0071.0098.0053.0091.0029067.0046.0017219163.00
  Inventory32.8%14.0010.009.008.004.00-----------
  Net PPE-7.1%2.002.002.002.002.002.002.002.002.002.002.002.000.000.000.000.00
Liabilities2.5%24624024024023810511011024.0018.0020.0028.0025.0023.0013.006.00
  Current Liabilities14.3%42.0037.0037.0038.0037.0027.0033.0033.0019.0013.0015.0023.0021.0019.0012.005.00
  Long Term Debt0.5%20120019919819773.0073.0072.00--------
    LT Debt, Non Current0.5%20120019919819773.0073.0072.00--------
Shareholder's Equity-42.0%47.0081.001402102711952542983634144512711732092421.00
  Retained Earnings-5.1%-915-870-799-719-647-540-472-408-337-280-237-201-167-129-94.28-66.30
  Additional Paid-In Capital1.1%9639529409309207377277067006956894733413393361.00
Shares Outstanding0.4%62.0062.0061.0061.0053.0051.0051.0050.0050.0050.0047.0036.00----
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations33.8%-43,984-66,485-80,344-71,065-67,695-61,980-56,975-51,709-40,884-35,831-46,203-32,571-33,691-25,761-21,010-16,797-10,722-8,243-7,074-
  Share Based Compensation-5.5%9,99910,5789,4799,2648,7898,0966,5335,6865,3634,3408,5032,6432,2612,04999045515413976.00-
Cashflow From Investing-48.9%45,54989,118107,75142,201-197,26252,56515,29723,4993,471-164,91961,996-75,892-91,7116,105-20,326-35,99921,096-2,152-9,270-
Cashflow From Financing-18.7%8671,067100962284,9891,13114,71672,88163.001,188207,815129,380-437309168,89392,955-20.00168--

ARQT Income Statement

2023-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenues:    
Total revenues$ 38,109$ 725$ 46,080$ 725
Operating expenses:    
Cost of sales1,1822692,741269
Research and development26,23669,73186,800148,558
Selling, general, and administrative47,59535,473136,47185,101
Total operating expenses75,013105,473226,012233,928
Loss from operations(36,904)(104,748)(179,932)(233,203)
Other income (expense):    
Other income, net2,7211,9389,1142,501
Interest expense(7,559)(4,899)(21,950)(8,737)
Loss before income taxes(41,742)(107,709)(192,768)(239,439)
Provision for income taxes3,02303,0880
Net loss(44,765)(107,709)(195,856)(239,439)
Other comprehensive income (loss):    
Unrealized income (loss) on marketable securities165(344)1,017(1,341)
Foreign currency translation adjustment(57)0(115)0
Total other comprehensive income (loss)108(344)902(1,341)
Comprehensive loss$ (44,657)$ (108,053)$ (194,954)$ (240,780)
Per share information:    
Net loss per share, basic (in USD per share)$ (0.73)$ (1.89)$ (3.19)$ (4.52)
Net loss per share, diluted (in USD per share)$ (0.73)$ (1.89)$ (3.19)$ (4.52)
Weighted-average shares used in computing net loss per share, basic (in shares)61,727,27857,091,74361,462,02553,028,962
Weighted-average shares used in computing net loss per share, diluted (in shares)61,727,27857,091,74361,462,02553,028,962
Product revenue, net    
Revenues:    
Total revenues$ 8,109$ 725$ 15,660$ 725
Other revenue    
Revenues:    
Total revenues$ 30,000$ 0$ 30,420$ 0

ARQT Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 107,471$ 53,641
Restricted cash9251,234
Marketable securities119,642355,948
Trade receivables, net19,4178,458
Inventories13,9137,514
Prepaid expenses and other current assets20,18010,611
Total current assets281,548437,406
Property, plant, and equipment, net1,7351,881
Intangible assets, net6,6257,188
Operating lease right-of-use asset2,4552,721
Other assets59678
Total assets292,959449,274
Current liabilities:  
Accounts payable13,1798,827
Accrued liabilities27,99528,323
Operating lease liability715657
Total current liabilities41,88937,807
Operating lease liability, noncurrent3,5704,117
Long-term debt, net200,783197,769
Total liabilities246,242239,693
Commitments and contingencies (Note 7)
Stockholders’ equity:  
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at September 30, 2023 and December 31, 2022; no shares issued and outstanding at September 30, 2023 and December 31, 2022;00
Common stock, $0.0001 par value; 300,000,000 shares authorized at September 30, 2023 and December 31, 2022; 61,861,736 and 61,052,250 shares issued at September 30, 2023 and December 31, 2022, respectively; 61,858,044 and 61,037,403 shares outstanding at September 30, 2023 and December 31, 2022, respectively66
Additional paid-in capital962,515930,425
Accumulated other comprehensive loss(184)(1,086)
Accumulated deficit(915,620)(719,764)
Total stockholders’ equity46,717209,581
Total liabilities and stockholders’ equity$ 292,959$ 449,274
ARQT
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical formulation of ivarmacitinib designed to reach deeper into the skin in order to treat alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
 CEO
 WEBSITEwww.arcutis.com
 EMPLOYEES268

Arcutis Biotherapeutics Inc Frequently Asked Questions


What is the ticker symbol for Arcutis Biotherapeutics Inc? What does ARQT stand for in stocks?

ARQT is the stock ticker symbol of Arcutis Biotherapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Arcutis Biotherapeutics Inc (ARQT)?

As of Thu Feb 22 2024, market cap of Arcutis Biotherapeutics Inc is 907.96 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ARQT stock?

You can check ARQT's fair value in chart for subscribers.

What is the fair value of ARQT stock?

You can check ARQT's fair value in chart for subscribers. The fair value of Arcutis Biotherapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Arcutis Biotherapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ARQT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Arcutis Biotherapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ARQT is over valued or under valued. Whether Arcutis Biotherapeutics Inc is cheap or expensive depends on the assumptions which impact Arcutis Biotherapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ARQT.

What is Arcutis Biotherapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 22 2024, ARQT's PE ratio (Price to Earnings) is -3.39 and Price to Sales (PS) ratio is 242.74. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ARQT PE ratio will change depending on the future growth rate expectations of investors.